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Abstract
Development of noninvasive, real-time molecular imaging tools to assess responsiveness of a given therapy may be
a critical component of the success of individualized therapy approach for patients. Toward this, we have previously
developed and validated molecular sensors for Akt and caspase-3 activity, and in this report, we have explored
the utility of these reporters in assessing the responsiveness of tumors to a combination of gemcitabine (Gem)
and cetuximab (Cet) delivered in two opposite schedules. We found that human head and neck cancer (UMSCC1)
xenografts responded significantly better in a schedule where cetuximab was administered after gemcitabine when
compared with the schedule of cetuximab followed by gemcitabine. Wilcoxon two-sample tests suggested that the
difference in tumor volumes in two schedules became significant on day 7 (P > .05 on day 4, and P < .05 on days 7
and 10), and the difference in activity of Akt in two schedules became significant on day 4 (P < .05 on days 4, 6, and
10). Using Akt reporter activity and cubic spline interpolation, the distinction between the two schedules could be
detected 2 days before using the tumor volume, suggesting that molecular imaging of Akt may allow early prediction
of therapy responsiveness. We did not observe a significant difference between the two schedules in the caspase-3
activity. In summary, this proof-of-concept study provides a basis for using molecular imaging of Akt as an early
indicator of therapeutic efficacy.
Translational Oncology (2011) 4, 122–125
Introduction
The advances in cellular and molecular biology in the past century have
made momentous progress in unraveling the molecular footprints of
tumorigenesis by identifying the abnormalities in signal transduction
pathways and gene alterations associated with cancer initiation and
propagation [1]. Although a number of biomarkers have been identi-
fied and their roles were construed, the true impact of these advances
is still not discernible in clinic. This is partly because most cancers are
extremely heterogeneous; current efforts focus mainly on identifying
biomarkers from cancer samples obtained by biopsy of tumors, which
provide a snapshot of biomarkers at the time of sample retrieval, and
fail to provide any information on the dynamic changes within the
malignancy and its milieu. Further, clinical diagnosis and outcome of
a therapy are still determined by the assessment of gross structural mea-
surements obtained several months after the therapy has been ad-
ministered. Therefore, the ability to predict therapeutic outcome early
into treatment will not only provide a unique opportunity to make
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informed clinical decisions on the efficacy of a particular therapy leading
to improvement in quality of life (by not subjecting them to a non-
efficacious therapy and/or shifting them to alternate regimen) but also
reduce expenses associated with nonefficacious therapies. Therefore,
there is an urgent need for molecular imaging tools for key signaling
intermediates [1]. In this vein, we have previously reported development
and validation of molecular imaging reporter for monitoring activities
of Akt kinase and caspase-3 protease [1–3]. Because both these enzymes
play a critical role in cell proliferation and apoptosis, they are good
candidates for investigating the potential of noninvasive imaging in
predicting early response.
The Akt/PKB, a serine/threonine kinase that is frequently upregu-
lated in a wide range of solid tumors and hematologic malignancies,
is a central signaling hub where many upstream oncogenic stimuli
(e.g., growth factor signaling/cytokine cascades) converge [4]. These
signals are then relayed by Akt to downstream intermediates, such
as NF-κB, mTOR, Forkhead, Bad, GSK-3, and MDM-2, which even-
tually modulate cellular processes such as proliferation, cell cycle pro-
gression, and protection from proapoptotic stimuli [5,6]. Because Akt
is one of the key oncologic targets, immense efforts have gone into
understanding its molecular biology and to develop novel therapeutic.
Existing modalities, such as immunoblot analysis or immunocyto-
chemistry using a phospho-Akt antibody [7], are invasive, cumbersome,
and only provide a snapshot view of the kinase activity at a specific
time point [5]. We recently developed a luciferase complementation–
based molecular imaging reporter for monitoring Akt activity (bio-
luminescent Akt reporter, BAR), which allows noninvasive and real-time
imaging of Akt activity both in vitro and in vivo. The high specificity
and sensitivity of this reporter were demonstrated in a number of dif-
ferent cancer cells such as UMSCC1 (head and neck cancer), D54 (glio-
blastoma), H1975 (lung cancer), HCC-H827 (lung cancer), and
DU145 (prostate cancer) and were validated using conventional tech-
niques such as immunohistochemistry, immunoprecipitation, and
immunoblot analysis [2] (Figures W1 and W2).
Caspase-3 also plays an important role in the activation of both
intrinsic and extrinsic apoptotic cascades. We had previously developed
a luciferase activity–based caspase-3 reporter [3] (see Supplementary
Results). Recently, we developed and validated a second-generation
caspase-3 reporter with a highly improved signal-to-noise ratio. This
reporter was based on luciferase complementation and was exploited
for the detection of caspase-3 activity both in vitro and in vivo [3].
In an experimental brain cancer therapeutic system using D54 xeno-
grafts, this molecular imaging reporter was used for optimizing doses
of temozolomide (Temodar) in combination with radiation [3]. Deter-
mination of bioluminescence activity within D54 tumor xenografts re-
vealed that control and irradiated animals had a minimal increase in
bioluminescence activity, whereas temozolomide-treated animals had a
nearly 50-fold increase. Further, animals treated with both temozolomide
and radiation therapy showed more than a 150-fold increase in bio-
luminescence activity which paralleled active caspase-3 staining, demon-
strating the high sensitivity and specificity of the reporter.
To test the utility of the Akt and caspase-3 reporters in early pre-
diction of therapeutic outcome, we used a system where we thought
that these signaling pathways may be important. We have previously
shown that the schedule of gemcitabine followed by gefitinib is better
than the converse schedule in inhibiting both cell cycle progression
and growth factor signaling [8]. Treatment of UMSCC1 cells with
gemcitabine followed by gefitinib resulted in arrest of cells in S-phase
concurrent with decreased Akt activity, increased poly(ADP-ribose)
polymerase cleavage, and increased apoptosis [8]. However, the
schedule of gefitinib followed by gemcitabine did not alter Akt ac-
tivity, and only minimal changes in poly(ADP-ribose) polymerase
cleavage and apoptosis were noticed. Similar results were also seen
in experiments in nude mice bearing UMSCC1 xenografts, in which
there was greater tumor regression and apoptosis when animals re-
ceived gemcitabine followed by gefitinib during the first week of
therapy. Thus, these schedules of combination therapies with dis-
tinct outcome would provide an ideal platform to investigate the ef-
fectiveness of real-time Akt and caspase-3 reporter activity as an early
predictor of therapeutic outcome.
Therefore, we decided to carry out a study to determine whether
these Akt or caspase-3 reporters could predict the outcome of treat-
ment of UMSCC1 xenografts by the combination of an epidermal
growth factor receptor inhibitor and gemcitabine. We found that the
schedule of gemcitabine followed by cetuximab (Gem → Cet) is
superior when compared with the opposite schedule (Cet → Gem)
in inhibition of Akt activity and tumor growth. We demonstrate that
significant differences in tumor volume were detected on day 7 (P =
.004) and day 10 (P < .0001) between the two schedules (Gem →
Cet vs Cet→ Gem). This system permitted us to test the effectiveness
of our reporter systems. Using Akt reporter such differences were de-
tected at earlier time points on day 4 (P = .05) and remained signifi-
cant until day 10 (P = .04), suggesting that molecular imaging of Akt
has the potential to allow early prediction of therapeutic response.
Materials and Methods
Cells Culture and In Vivo Imaging
UMSCC1 (human head and neck squamous carcinoma) cells were
a gift from Thomas Carey, University of Michigan. UMSCC1 cells
expressing BAR and caspase-3 reporter were generated as described
previously [2,3,9]. Animal protocols were approved by the Univer-
sity Committee on the Use and Care of Animals at the University of
Michigan. Before use, UMSCC1-BAR or UMSCC1-ANlucBCluc
cells were trypsinized, counted, and suspended in serum-free RPMI
medium for tumor implantation. Six- to eight-week-old nu/nu athymic
male mice were maintained in ventilated cages and fed/watered
ad libitum. Using sterile syringe and 22-gauge needle, 5 × 106 cells were
then injected in a total volume of 50 μl subcutaneously at four sites
as shown in Figure 1A. When tumor became palpable, mice were
randomly divided into two groups (n = 5 per group), and then the
treatment was started as shown in Figure 2, A and B. Briefly, mice
were injected with either cetuximab (50 mg/kg, intraperitoneally) or
gemcitabine (300 mg/kg, intraperitoneally) followed by gemcitabine
or cetuximab injection next day. Bioluminescence imaging of the ani-
mals were performed as previously described [2,3,10]. Tumor volumes
were recorded on days 0, 3, 6, and 9.
Statistical Methods
Wilcoxon two-sample test was used to compare tumor volumes, Akt
and caspase-3 between two schedules (Gem → Cet vs Cet → Gem).
Spline function was applied to the observed volume measurements
(at 24, 96, 168, and 240 hours) to interpolate volumes every 24 hours
until 240 hours. Similarly, Akt measurements were interpolated every
24 hours from 96 to 240 hours using the observed Akt measurements
(at 25, 96, 144, and 240 hours). Wilcoxon two-sample tests were used
to compare schedules at each time point (Gem→ Cet vs Cet→ Gem)
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Figure 1. Outcome of two different schedule of gemcitabine and cetuximab combination therapy as measured by (AKT) anatomic changes.
(A) Schematic representation of the UMSCC1 xenografts in nude mice where UMSCC1 cells expressing the BAR were subcutaneously
implanted on the left dorsal side at both rostral and caudal regions. On the right dorsal side, caspase-3 reporter (ANlucBCluc) –bearing
UMSCC1 tumor xenografts were generated. A group of five animals were subjected to one of the two schedules: Either gemcitabine fol-
lowed by C225 (Gem→ C225) or C225 followed by gemcitabine (C225→ Gem). (B) Tumor volumes as measured by digital calipers were
plotted for each of the two schedules described above. Data are plotted as mean of 10 tumors ± SEM. (C) Wilcoxon two-sample test was
used to compare tumor volumes between the two schedules (C225→ Gem vs Gem→ C225).
Figure 2. Molecular imaging of two schedules of gemcitabine and cetuximab combination therapy using bioluminescence Akt and
caspase-3 reporters. Nude mice were implanted with UMSCC1 xenografts expressing either BAR or ANlucBCluc reporters as demon-
strated in Figure 1A. An increase in bioluminescence activity of Akt reporter indicates an increase in inhibition of Akt activity [2], whereas
an increase in caspase-3 reporter activity is indicative of increased caspase-3 dependent apoptosis [3]. Representative overlay of bio-
luminescent acquisition and light photographs are shown in A for the gemcitabine-followed-by-cetuximab schedule and in B for the
cetuximab-followed-by-gemcitabine schedule. (C) Wilcoxon two-sample test was used to compare schedules (Cet → Gem vs Gem →
Cet) bioluminescent data obtained by BAR (n = 10 per schedule) and ANlucBCluc reporter (n = 9 per schedule). The increase in bio-
luminescence activity refers to an increase in caspase-3 activity.
124 Molecular Imaging to Assess Therapeutic Response Bhojani et al. Translational Oncology Vol. 4, No. 3, 2011
using these interpolated data from tumors that have both volume and
Akt measurements (n = 9 per schedule).
Results and Discussion
Molecular Imaging of Akt Predicts Responsiveness
of Tumors to Therapy
To investigate whether imaging of Akt and the caspase-3 reporter
activity could be exploited to determine therapeutic response earlier
than conventional anatomic modalities, we generated mice bearing
human UMSCC1 xenografts expressing the BAR and caspase-3 re-
porter (ANlucBCluc) as shown in Figure 1A. Once tumors were pal-
pable, mice (n = 5 per group) were treated with either gemcitabine
on day 1 followed by cetuximab on day 2 (Gem→ Cet) or cetuximab
on day 1 followed gemcitabine day 2 (Cet → Gem). Tumors in ani-
mals treated with gemcitabine followed by cetuximab were notably
smaller when compared with mice treated with cetuximab followed
by gemcitabine. Quantification of tumor volumes showed a clear bi-
furcation in the two groups from day 7 onward (Figure 1B). Significant
differences in the tumor volumes between the two schedules (Gem→
Cet vs Cet → Gem) were detected on days 7 and 10 (P = .004 and
P < .0001; Figure 1C).
In addition to tumor volumes, AKT (BAR) and caspase-3
(ANlucBCluc) bioluminescence was monitored in both groups before
therapy and 7 hours after each treatment followed by daily measure-
ments (Figure 2). Representative images of bioluminescence acquisition
are shown in Figure 2. Spline function was applied to the observed
volume measurements (on days 1, 4, 6, and 10) to interpolate data
every 24 hours from day 4 to 10 using the Akt measurements (Table 1).
Wilcoxon two-sample tests suggested significant differences were de-
tected from day 6 to day 10 based on volumes and was detected from
day 4 to day 10 based on molecular imaging of Akt, respectively
(Table 1A). Akt activity was negatively correlated with tumor volume
measurements at all the time points where two schedules had signifi-
cant differences (Table 1B). Interestingly, there was no significant differ-
ence in caspase-3 activity at any of the time points analyzed (Figure 2),
suggesting that caspase-3–dependent apoptosis may not play a major
role in the difference observed between the two schedules. Cetuximab
has been reported to modulate autophagic clearance of the cells, and this
may partly explain the lack of difference in caspase-3 activity in the two
schedules and correlation between tumor volume and caspase-3 activity
(data not shown).
In summary, we detected tumor volume differences between these
two schedules only at 144 hours but found significance difference in
Akt activity at 96 hours. Thus, our results suggest that molecular
imaging of Akt has the potential to detect outcome of treatment earlier
than using the volume end point (Table 1A). Because multiple onco-
genic pathways mediate their effects through Akt, contributing to the
central role of Akt in cell proliferation and survival, Akt reporters will
greatly facilitate early prediction of efficacy of other molecular targeted
drugs that impinge on activity.
Because molecular imaging techniques are noninvasive, repetitive
imaging of the same cohort of animals at different time points not only
provide a unique method to predict efficacy of a therapeutic regimen
but also monitor drug-target interactions and pharmacodynamics of
drug in real time. When compared with the cumbersome conventional
methods that are based on euthanizing of animals at different time
points for assessing changes in signaling, molecular imaging provides
a significant reduction in pain and the cost associated with in vivo
investigations. A major limitation of such genetic sensors is that the
reporter needs to be transfected into tumor cells to monitor its ac-
tivity. Thus, such reporter will have limited utility in clinic. Thus,
until nongenetic molecular imaging assays are developed, luciferase
complementation–based reporters may be used for target validation
and dose and schedule optimization in preclinical models as well as
providing for rapid identification of lead compounds from a library
using cell-based, high-throughput screening.
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Table 1. Early Prediction of Therapeutic Response by Molecular Imaging of Akt Activity When
Compared with Anatomic Changes within the Tumor.
(A) P Based on Interpolated Tumor Volume and AKT or Caspase Photon Counts
T96 T120 T144 T168 T192 T216 T240
Volume 0.34 0.08 0.01 0.01 0.005 0.004 0.005
AKT 0.01 0.01 0.01 0.02 0.01 0.01 0.02
Caspase NA NA NA NA NA NA NA
(B) Correlations Based on Observed AKT and Tumor Volume Measurements
T24 T96 T168 T240
T25 0.02 0.09 −0.04 −0.13
T96 0.08 0.19 −0.43 −0.6
T144 −0.2 −0.18 −0.64 −0.55
T240 0.04 0.06 −0.3 −0.44
Spline function was applied to the observed volume measurements (at 24, 96, 168, and 240 hours)
to interpolate volumes every 24 hours until 240 hours. Similarly, Akt measurements were inter-
polated every 24 hours from 96 to 240 hours using the observed Akt measurements (at 25, 96,
144, and 240 hours). (A) Wilcoxon two-sample tests were used to compare schedules (cetuximab→
Gem vsGem→ cetuximab) using these interpolated data from tumors that have both tumor volume
and Akt measurements (n = 10 per schedule). Caspase data were not interpolated because no signif-
icant difference was detected for all time points. Observed correlation between actual tumor volumes
and relative bioluminescent Akt activity are presented in B. Because an increase in bioluminescent
AKTreporter activity is monitored when the Akt kinase is inhibited, the negative value in B represents
this inverse relationship between Akt kinase (or BAR) activity.
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Figure W1. Characterization of Akt reporter in UMSCC1 cells.
(A) UMSCC1 cells stably transfected with Akt reporter were treated
with either 2 μM erlotinib or 10 μM API-2. Change in the biolumi-
nescence activity was measured and plotted as percent change
over pretreatment values. Mean values from three independent
experiments are plotted. Error bars, SEM. (B) Inhibition of Akt activity
was confirmed by immunoblot analysis of the cell lysate 1 hour after
treatment as shown in A using antibodies specific for phospho-Akt
or total Akt.
Figure W2. Characterization of caspase-3 reporter in UMSCC1 cells.
(A) UMSCC1 cells stably transfected with caspase-3 reporter were
treated with perifosine (9 μM) or vehicle, and bioluminescence was
measured. Data are derived from three independent experiments and
are plotted as described in Figure W1. (B) Activation of caspase-3 was
confirmed by immunoblot analysis of the lysate from this experiment
using antibodies specific for active caspase-3.
